GSK GSK-0.10%decrease; red down pointing triangle shares topped the Stoxx Europe 600 index on Thursday after the pharmaceutical company agreed to pay up to $2.2 billion to settle thousands of U.S ...

GSK Plc CEO Emma Walmsley doesn’t want the company’s employees spending any time thinking about the ongoing litigation over its old heartburn drug Zantac, an issue that has weighed on the ...

That news concerns a discontinued version of GSK's blockbuster heartburn drug Zantac, which was the focus of a series of lawsuits alleging that its active ingredient caused cancer. GSK announced ...

Oct 8 (Reuters) - GSK (GSK.L), opens new tab said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in its third season after patients ...

Simply sign up to the Pharmaceuticals sector myFT Digest -- delivered directly to your inbox. GSK’s ex-head of vaccines says its blockbuster jab for a flu-like virus that spreads in the autumn ...

GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...

GSK will pay up to $2.2 billion to resolve 93% of U.S. Zantac cases. GSK expects to recognize a £1.8 billion ($2.3 billion) charge in Q3 2024 related to these settlements. These cases account for ...

GSK Plc’s experimental drug to treat a common inflammatory nasal condition showed positive results in two late-stage trials in a boost for the UK drugmaker’s pipeline. Depemokimab helped ...

GSK recently announced the discontinuation of its herpes simplex virus (HSV) therapeutic vaccine candidate, GSK3943104, following the failure of a Phase I/II clinical trial to meet its primary ...

FDA accepted GSK's gepotidacin application for uUTI treatment with a PDUFA date set for March 26, 2025. Gepotidacin showed superior efficacy over nitrofurantoin in EAGLE-3 trial with a 58.5% ...